Novel Anti-Helicobacter Pylori Therapies

References

• Alakkari A Zullo A O’Connor HJ . Helicobacter pylori and nonmalignant diseases. Helicobacter16 (Suppl. 1), 33–37 (2011).
   PubMedGoogle Scholar
• Delahay RM Rugge M . Pathogenesis of Helicobacter pylori infection. Helicobacter17 (Suppl. 1), 9–15 (2012).
   PubMedGoogle Scholar
• Campo SMA Zullo A Hassan C Morini S . Antibiotic treatment strategies for Helicobacter pylori infection. Recent Pat. Antiinfect. Drug Discov.2, 11–17 (2007).
   PubMedGoogle Scholar
• Malfertheiner P Megraud F O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut61, 646–664 (2012).
   PubMed Web of Science ®Google Scholar
• O’Rourke J Bode G . Chapter 6: Morphology and Ultrastructure. In:Helicobacter pylori: Physiology and Genetics Mobley HLT, MendzGLHazellSL (Eds). ASM Press, Washington, DC, USA (2001).
   Google Scholar
• Warren JR Marshall B . Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet321 (8336), 1273–1275 (1983).
   Google Scholar
• Goodwin CS Armstrong JA Chilvers T et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively. Int. J. Syst. Bacteriol.39 (4), 397–405 (1989).
   Google Scholar
• Ohno T Vallström A Rugge M et al. Effects of blood group antigen-binding adhesin expression during Helicobacter pylori infection of mongolian gerbils. J. Infect. Dis.203 (5), 726–735 (2011).
   PubMed Web of Science ®Google Scholar
• Papamichael K Mantzaris GJ . Pathogenesis of Helicobacter pylori infection: colonization, virulence factors of the bacterium and immune and non-immune host response. Hospital Chronicals7 (1), 32–37 (2012).
   Google Scholar
• Matsuda K Yamauchi K Matsumoto T Sano K Yamaoka Y Ota H . Quantitative analysis of the effect of Helicobacter pylori on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells. Scand. J. Gastroenterol.43 (1), 25–33 (2008).
   PubMed Web of Science ®Google Scholar
• Amieva MR El-Omar EM . Host–bacterial interactions in Helicobacter pylori infection. Gastroenterology134 (1), 306–323 (2008).
   PubMed Web of Science ®Google Scholar
• De Francesco V Ierardi E Hassan C Zullo A . Helicobacter pylori therapy: Present and future. World J. Gastrointest. Pharmacol. Ther.3 (4), 68–73 (2012).
   PubMedGoogle Scholar
• Fiorini G Zullo A Gatta L et al. Newer agents for Helicobacter pylori eradication. Clin. Exp. Gastroenterol.5, 109–112 (2012).
   PubMedGoogle Scholar
• De Francesco V Giorgio F Hassan C et al. Worldwide H. pylori antibiotic resistance: a systemic review. J. Gastrointestin. Liver Dis.19 (4), 409–414 (2010).
   PubMed Web of Science ®Google Scholar
• Sancheza JE Saenza NG Rinconb MR Martina IT Sancheza EG Martineza MJ . Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob. Chemother.46, 283–285 (2000).
   PubMed Web of Science ®Google Scholar
• Wedemeyer RS Blume H . Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf.7 (4), 201–211 (2014).
   Google Scholar
• Shin JM Homerin M Domagala F Ficheux H Sachs G . Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K+ -ATPase in vitro and in vivo. Biochem. Pharmacol.71 (6), 837–849 (2006).
   PubMed Web of Science ®Google Scholar
• Metz DC Vakily M Dixit T Mulford D . Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment. Pharmacol. Ther.29 (9), 928–937 (2009).
   PubMed Web of Science ®Google Scholar
• Wang L Zhou L Lin S Hu H Xia J . A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J. Clin. Gastroenterol.45 (4), 322–329 (2011).
   PubMed Web of Science ®Google Scholar
• Pai V Pai N . Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol.14, 4100–4102 (2007).
   Google Scholar
• Santarus Inc. : US0092658 (2009).
   Google Scholar
• Accumed LLC, Q-Pharma LLC : US0057125 (2008).
   Google Scholar
• Chuah S-K Tsay FW Hsu P-I Wu D-C . A new look at anti-Helicobacter pylori therapy. World J. Gastroenterol.17 (35), 3971–3975 (2011).
   PubMed Web of Science ®Google Scholar
• Graham DY . Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol.7, 145–148 (2009).
   PubMed Web of Science ®Google Scholar
• Vakil N Megraud F . Eradication therapy for Helicobacter pylori. Gastroenterology133, 985–1001 (2007).
   PubMed Web of Science ®Google Scholar
• Thirumurthi S Graham DY . Helicobacter pylori infection in India from a western perspective. Ind. J. Med. Res.136, 549–562 (2012).
   PubMed Web of Science ®Google Scholar
• Zullo A Hassan C D’Ercole C D Francesco V Vaira D . Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication?Aliment. Pharmacol. Ther.31 (11), 1248–1249 (2010).
   PubMed Web of Science ®Google Scholar
• Eisai R&D Management Co. Ltd : US0110727 (2009).
   Google Scholar
• Flamel Technologies SA : US0068291 (2010).
   Google Scholar
• AstraZeneca AB : US0095853 (2008).
   Google Scholar
• Apta Pharma Inc. : US0280175 (2009).
   Google Scholar
• Intellipharmaceuticals Corp. : US0129442 (2010).
   Google Scholar
• The Curators of the University of Missouri : US8247440 (2012).
   Google Scholar
• Cadila Healthcare Ltd. : US0216617 (2013).
   Google Scholar
• Dermatrends Inc. : US0287502 (2008).
   Google Scholar
• Yun SP Son SG Ok CS et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver6 (4), 452–456 (2012).
   PubMed Web of Science ®Google Scholar
• Strides Arcolab Ltd : WO0044093 (2010).
   Google Scholar
• Basu PP Rayapudi K Pacana T Shah NJ Krishnaswamy N Flynn M . A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am. J. Gastroenterol.106 (11), 1970–1975 (2011).
   PubMed Web of Science ®Google Scholar
• Monash University : US0086911 (2011).
   Google Scholar
• Fakheri H Bari Z Sardarian H . A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter17 (4), 264–268 (2012).
   PubMed Web of Science ®Google Scholar
• Hsu P-I Chen W-C Tsay F-W et al. On behalf of the Taiwan Acid-Related Disease (TARD) Study Group. Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter19 (1), 74–79 (2014).
   PubMed Web of Science ®Google Scholar
• Nycomed GMBH/Takeda Pharmaceutical Company Ltd : US0189590 (2007).
   Google Scholar
• Cipla Ltd : US0161579 (2008).
   Google Scholar
• Takeda Pharmaceutical Company Ltd : US0028476 (2011).
   Google Scholar
• Lek Pharmaceuticals DD : US0046319 (2012).
   Google Scholar
• Nycomed GMBH : US0022779 (2010).
   Google Scholar
• Alevium Pharmaceuticals, Inc. : US0317689 (2010).
   Google Scholar
• Allergan, Inc. : US0060621 (2007).
   Google Scholar
• Altana pPharma AG/Nycomed GMBH : US0244115 (2007).
   Google Scholar
• Sidem Pharma : US7402593 (2008).
   Google Scholar
• Chongqing University of Technology : CN103102302 A (2013).
   Google Scholar
• Chongqing University of Technology : CN103113295 (2013).
   Google Scholar
• Achaogen Inc. : WO1031745 (2011).
   Google Scholar
• Yang JC Lee PI Hsueh PR . In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007. Eur. J. Clin. Microbiol. Infect. Dis.29 (11), 1369–1375 (2010).
   PubMed Web of Science ®Google Scholar
• Taigen Biotechnology Co. Ltd : US8211909 (2012).
   Google Scholar
• Lahner E Persechino S Annibale B . Micronutrients (other than iron) and Helicobacter pylori infection: a systemic review. Helicobacter17 (1), 1–15 (2012).
   PubMed Web of Science ®Google Scholar
• Yale University, NIH : US0150861 (2010).
   Google Scholar
• Souls Disinfectant Co Ltd : CN102088984 (2012).
   Google Scholar
• Vitor JMB Vale FF . Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol. Med. Microbiol.63, 153–164 (2011).
   PubMedGoogle Scholar
• Gotteland M Brunser O Cruchet S . Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?Aliment. Pharmacol. Ther.23, 1077–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Dikovskiy AV Dorozhko OV : US0028914 (2012).
   Google Scholar
• De Bortoli N Leonardi G Ciancia E et al. Helicobacter pylori eradication: a randomized, prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol.102, 951–956 (2007).
   PubMed Web of Science ®Google Scholar
• Auckland Uniservices Ltd : US0214618 (2008).
   Google Scholar
• Figura N Marcolongo R Cavallo G et al. Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study. BMC Microbiol.12, 217 (2012).
   PubMed Web of Science ®Google Scholar
• Over SRL : US0217641 (2013).
   Google Scholar
• Goswami S Bhakuni RS Chinniah A Pal A Kar SK Das PK . Anti-Helicobacter pylori potential of artemisinin and its derivatives. Antimicrob. Agents Chemother.56 (9), 4594–4607 (2012).
   PubMed Web of Science ®Google Scholar
• Marash M Kluev E : WO5048912 (2005).
   Google Scholar
• Hagen SJ Ohtani M Zhou J-R et al. Inflammation and foveolar hyperplasia are reduced by supplemental dietary glutamine during Helicobacter pylori infection in mice. J. Nutr.139 (5), 912–918 (2009).
   PubMed Web of Science ®Google Scholar
• Nishida H Hasuoka A Arikawa Y et al. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg. Med. Chem.20, 3925–3938 (2012).
   PubMed Web of Science ®Google Scholar
• Lee J-S Cho J-Y Song H Kim E-H Hahm K-B . Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J. Clin. Biochem. Nutr.51 (2), 77–83 (2012).
   PubMed Web of Science ®Google Scholar
• Jung JW Kang HR Kwon JW et al. The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. Tohoku J. Exp. Med.224 (4), 293–300 (2011).
   PubMed Web of Science ®Google Scholar
• Yuhan Corporation : WO2108631 (2012).
   Google Scholar
• Inatomi N Matsukawa J . A new gastric acid suppressant: potassium-competitive acid blocker, TAK-438. Med. Sci. Digest38 (12), 546–550 (2012).
   Google Scholar
• Takeda Pharmaceutical Company : WO8108380 (2008).
   Google Scholar
• Raqualia Pharma Inc. : US0048532 (2010).
   Google Scholar
• Raqualia Pharma Inc. : US0214519 (2008).
   Google Scholar
• Innovative Pharmacology Research OOO : US0329804 (2013).
   Google Scholar
• Scarpignato C Hunt RH . Proton pump inhibitors: the beginning of the end or the end of the beginning?Curr. Opin. Pharmacol.8 (6), 677–684 (2008).
   PubMed Web of Science ®Google Scholar
• Nitromed Inc. : US0179150 (2007).
   Google Scholar
• Univ Boston : WO8019292 (2008).
   Google Scholar
• Wockhardt Research Centre : WO1101710 (2011).
   Google Scholar
• Shionogi and Co. : US0116493 (2004).
   Google Scholar
• Solomon LR Cheesbrough JS Ebah L et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am. J. Kidney Dis.55 (6), 1060–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Polaschegg H-D : US0085469 (2013).
   Google Scholar
• Nabriva Therapeutics AG : US7790749 (2010).
   Google Scholar
• Shang R Wang J Guo W Liang J . Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr. Top. Med. Chem.13 (24), 3013–3025 (2013).
   PubMed Web of Science ®Google Scholar
• Makobongo MO Einck L Peek RM Jr Merrell DS . In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS ONE8 (7), e68917 (2013).
   PubMed Web of Science ®Google Scholar
• Sequella Inc. : US7884097 (2011).
   Google Scholar
• Rothstein DM Mullin S Sirokman K et al. Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization. J. Antibiot. (Tokyo)61 (8), 485–488 (2008).
   PubMed Web of Science ®Google Scholar
• Cabana BE Magnant GP Michaelis AF Sayda CB . US0046281 (2012).
   Google Scholar
• Activbiotics Pharma, LLC : WO0005836 (2010).
   Google Scholar
• Activbiotics Pharma, LLC : US7820652 (2010).
   Google Scholar
• Arigen Pharmaceuticals Inc. : US0173944 (2010).
   Google Scholar
• Arigen Pharmaceuticals Inc. : US0143438 (2009).
   Google Scholar
• Asadipour A Edraki N Nakhjiri M et al. Anti-Helicobacter pylori activity and structure-activity relationship study of 2-alkylthio-5-(nitroaryl)-1,3,4-thiadiazole derivatives. Iran. J. Pharm. Res.12 (3), 281–287 (2013).
   PubMed Web of Science ®Google Scholar
• Arigen Pharmaceuticals Inc. : US0041030 (2012).
   Google Scholar
• Chemeq Ltd : US7629002 (2009).
   Google Scholar
• Aoki W Ueda M . Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals (Basel)6 (8), 1055–1081 (2013).
   PubMedGoogle Scholar
• Makobongo MO Gancz H Carpenter BM McDaniel DP Merrell S . The oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob. Agents Chemother.56 (1), 378–390 (2012).
   PubMed Web of Science ®Google Scholar
• Okuda M Yamamoto N Fukuda N et al. Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection. J. Gastroenterol. Hepatol.27 (Suppl. 3), 100–102 (2012).
   PubMedGoogle Scholar
• Tanabe Seiyaku Co. : WO3028716 (2003).
   Google Scholar
• Wang Y Tang N Meng L et al. Safety and tolerability of bismuthyl Ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects. Clin. Drug Invest.32 (4), 247–252 (2012).
   PubMed Web of Science ®Google Scholar
• National University of Ireland, Dublin : WO3004669 (2013).
   Google Scholar
• National Tsing Hua University : US8175860 (2012).
   Google Scholar
• Council Scient. Ind. RES : WO8015524 (2008).
   Google Scholar
• Strugatsky D McNulty R Munson K et al. Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori. Nature493, 255–258 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng C-S Jia K-F Chen T Chang S-Y Lin M-S Yin H-S . Experimentally validated novel inhibitors of Helicobacter pylori phosphopantetheine adenylyltransferase discovered by virtual high-throughput screening. PLoS ONE8 (9), e74271 (2013).
   PubMed Web of Science ®Google Scholar
• Rivera-Ordaz A Bracher S Sarrach S et al. The sodium/proline transporter PutP of Helicobacter pylori. PLoS ONE8 (12), e83576 (2013).
   PubMed Web of Science ®Google Scholar
• Zou Q-H Wei W . Phage. therapy: promising for H. pylori infection. Clin. Microbiol. (Tokyo)2, 112 (2013).
   Google Scholar
• Universidad de Zaragoza : US0317862 (2010).
   Google Scholar
• Warren CA van Opstal E Ballard TC et al. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob. Agents Chemother.56 (8), 4103–4111 (2012).
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company Ltd : US7671174 (2010).
   Google Scholar
• Takeda Pharmaceutical Company Ltd : US0227501 (2009).
   Google Scholar
• Giudice GD Malfertheiner P Rappuoli R . Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines8 (8), 1037–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Life Spring Immuno Science Corp. : US0011437 (2013).
   Google Scholar
• Summerton NA Welch RW Bondoc L et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine28, 1404–1411 (2010).
   PubMed Web of Science ®Google Scholar
• Helicure AB : US8025880 (2011).
   Google Scholar
• Caselli M Cassol F Calo G Holton J Zuliani G Gasbarrini A . Actual concept of 'probiotics': is it more functional to science or business?World J. Gastroenterol.19 (10), 1527–1540 (2013).
   PubMed Web of Science ®Google Scholar
• Bioengineering Institute of Military Medical Sciences : CN101863964 (2013).
   Google Scholar
• Chongqing Kang Wei Biotechnology Co. Ltd : IP252901 (2012).
   Google Scholar
• Hongying F Xianbo W Fang Y Yang B Beiguo L . Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin. Vaccine Immunol.21, 126–132 (2014).
   PubMed Web of Science ®Google Scholar
• Novartis Vaccines and Diagnostics Inc. : US7901907 (2011).
   Google Scholar
• Rican Ltd : IP240197 (2010).
   Google Scholar
• Inoue K Shiota S Yamada K et al. A evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen. Helicobacter14, 135–143 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SJ Lee JY Jun DY et al. Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice. FEMS Immunol. Med. Microbiol.57, 257–268 (2009).
   PubMedGoogle Scholar
• Malfertheiner P Schultze V Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterol.135, 787–895 (2008).
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University : CN102178941 (2013).
   Google Scholar
• AstraZeneca AB : US6838089 (2005).
   Google Scholar
• Amaral MRRL Goncalves L Almeida A . Evaluation of a new vaccine based on pDNA and recombinant protein against Helicobacter pylori. www.hdl.handle.net/10362/8520
   Google Scholar
• Figueiredo L Calado CCR Almeida AJ Goncalves LMD . Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: in vivo evaluation. Presented at:IEEE 2nd Portuguese Meeting in English.Coimbra, Portugal23–25 February 2012.
   Google Scholar
• Talebkhan Y Bababeik M Esmaeili M et al. Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. J. Microbiol. Methods82 (3), 334–337 (2010).
   PubMed Web of Science ®Google Scholar
• Medical and Pharmaceutical Industry Technology and Development Center : US8470379 (2013).
   Google Scholar
• Ceramoptec Industries Inc. : US0245198 (2011).
   Google Scholar
• Arjuna Natural Extracts, Ltd : US0207863 (2012).
   Google Scholar
• Arjuna Natural Extracts, Ltd. : US7883728 (2008).
   Google Scholar
• Sologran Ltd : US0039816 (2011).
   Google Scholar
• Messing J Thole C Niehues M et al. Antiadhesive properties of Abelmoschus esculentus (Okra) immature fruit extract against Helicobacter pylori adhesion. PLoS ONE9 (1), e84836 (2014).
   PubMed Web of Science ®Google Scholar
• Yamaguchi K Kono T : US8241683 (2012).
   Google Scholar
• Martini S D‘Addario C Colacevich A et al. Antimicrobial activity against Helicobacter pylori strains and antioxidant properties of blackberry leale (Rubus ulmifolius) and isolated components. Int. J. Antimicrob. Agents34, 50–59 (2009).
   PubMed Web of Science ®Google Scholar
• Rasmussen LT de Labio RW Gatii LL et al. Helicobacter pylori detection in gastric biopsies, saliva and dental plaque of Brazilian dyspeptic patients. Mem. Inst. Oswaldo Cruz105 (3) 326–330 (2010).
   PubMed Web of Science ®Google Scholar